Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piperacillin-Tazobactam Continuous vs Intermittent Infusion for Pseudomonas Infection
NCT01577368Phase 3Completed
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- May 2011
- Primary completion
- Jan 2014
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of piperacillin + tazobactam in Pseudomonas aeruginosa infection, sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Started May 2011; status: completed.
02
Drugs
piperacillin + tazobactam
03
Conditions
Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT01577368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01577368.